Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as Financial PR & Investor Relations advisor to AIM and Euronext listed Open Orphan plc, a rapidly growing specialist pharmaceutical services CRO which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials. The team at Walbrook will manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.
Open Orphan conducts human challenge studies from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms which are connected to a specialist laboratory facility. hVIVO's challenge studies require healthy volunteers to take part, with volunteers recruited through FluCamp (you can learn more at www.FluCamp.com). The hVIVO facility offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development. Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples.
In October 2020, the Company signed a contract with the UK Government to develop a COVID-19 human challenge study model. The study will enable better understanding of the virus and play a vital role in speeding up the development of an effective vaccine.
For more information visit the Company’s website: https://www.openorphan.com/
Paul McManus, Founder and Managing Director of Walbrook PR, commented: “We are very excited to be working with Open Orphan plc. The Company is playing an essential role in the fight against COVID-19 with the development of the world’s first COVID-19 characterisation study, which is expected to receive ethics approval in the near term. Furthermore, the Company is perfectly placed as the world leader in the trialing of vaccines and antivirals using human challenge models as we enter a decade of unprecedented spending on vaccine development. We are looking forward to helping Open Orphan as they continue to achieve new and exciting commercial milestones.”
For further information please contact:
About Walbrook PR: www.walbrookpr.com
Walbrook PR was founded in April 2009 by Paul McManus and focuses on providing high quality Financial PR and Investor Relations to Small Cap and AIM listed companies.
Walbrook PR is ranked 2nd in the AIM Adviser Rankings guide and is ranked 7th by total number of Stock Market listed clients. Walbrook acts for 56 listed companies (mainly AIM) across a wide mix of sectors and is ranked 1st in Healthcare and 4th in Technology, by number of AIM clients.
Walbrook PR prides itself on having a strong reputation for working with growing UK Small Cap and AIM listed companies; a proven IR offering, which focuses on the Private Client Investment Management community and the retail investment community; and on having a proactive, hands-on approach from a committed team with full ownership of the business.